Related references
Note: Only part of the references are listed.Esketamine: a glimmer of hope in treatment-resistant depression
Upinder Kaur et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2021)
First-in-man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M1-receptor partial agonist for the treatment of dementias
Charlotte Bakker et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer's disease
Alastair J. H. Brown et al.
CELL (2021)
Site-independent confirmation of primary site-based PANSS ratings in a schizophrenia trial
Steven D. Targum et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2021)
Development of an In Silico Prediction Model for P-glycoprotein Efflux Potential in Brain Capillary Endothelial Cells toward the Prediction of Brain Penetration
Reiko Watanabe et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Novel Antimuscarinic Antidepressant-like Compounds with Reduced Effects on Cognition
Chad R. Johnson et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2021)
Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia
Stephen K. Brannan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M1 receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study
Charlotte Bakker et al.
ALZHEIMERS RESEARCH & THERAPY (2021)
Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression
Jennifer L. Phillips et al.
NEUROPSYCHOPHARMACOLOGY (2020)
Discovery of [11C]MK-6884: A Positron Emission Tomography (PET) Imaging Agent for the Study of M4Muscarinic Receptor Positive Allosteric Modulators (PAMs) in Neurodegenerative Diseases
Ling Tong et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data
Michel Nijs et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2020)
Dysregulation of Midbrain Dopamine System and the Pathophysiology of Schizophrenia
Susan F. Sonnenschein et al.
FRONTIERS IN PSYCHIATRY (2020)
Examining the role of muscarinic M5 receptors in VTA cholinergic modulation of depressive-like and anxiety-related behaviors in rats
Eric J. Nunes et al.
NEUROPHARMACOLOGY (2020)
Muscarinic M1 and M4 receptors: Hypothesis driven drug development for schizophrenia
Brian Dean et al.
PSYCHIATRY RESEARCH (2020)
Cognitive performance effects following a single dose of the M 1 muscarinic positive allosteric modulator VU319
Alexander C. Conley et al.
Alzheimers & Dementia (2020)
Safety and pharmacokinetics of the muscarinic positive allosteric modulator VU319: A phase 1 single dose study
Paul A. Newhouse et al.
Alzheimers & Dementia (2020)
The role of dissociation in ketamine's antidepressant effects
Elizabeth D. Ballard et al.
NATURE COMMUNICATIONS (2020)
Discovery of Tricyclic Triazolo- and Imidazopyridine Lactams as M1 Positive Allosteric Modulators
Julie L. Engers et al.
ACS CHEMICAL NEUROSCIENCE (2019)
Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts
Eric A. Wold et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Cholinergic regulation of mood: from basic and clinical studies to emerging therapeutics
Stephanie C. Dulawa et al.
MOLECULAR PSYCHIATRY (2019)
TAK-071, a novel M1 positive allosteric modulator with low cooperativity, improves cognitive function in rodents with few cholinergic side effects
Yuu Sako et al.
NEUROPSYCHOPHARMACOLOGY (2019)
Discovery, Optimization, and Biological Characterization of 2,3,6-Trisubstituted Pyridine-Containing M4 Positive Allosteric Modulators
Jeffrey W. Schubert et al.
CHEMMEDCHEM (2019)
The high efficacy of muscarinic M4 receptor in D1 medium spiny neurons reverses striatal hyperdopaminergia
Anu G. Nair et al.
NEUROPHARMACOLOGY (2019)
Discovery of Selective M4 Muscarinic Acetylcholine Receptor Agonists with Novel Carbamate Isosteres
Qingyi Yang et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study
Carol A. C. Coupland et al.
JAMA INTERNAL MEDICINE (2019)
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial
Ella J. Daly et al.
JAMA PSYCHIATRY (2019)
A Receptor Model With Binding Affinity, Activation Efficacy, and Signal Amplification Parameters for Complex Fractional Response Versus Occupancy Data
Peter Buchwald
FRONTIERS IN PHARMACOLOGY (2019)
Widespread Changes in Positive Allosteric Modulation of the Muscarinic M1 Receptor in Some Participants With Schizophrenia
Shaun Hopper et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2019)
Translating preclinical findings in clinically relevant new antipsychotic targets: focus on the glutamatergic postsynaptic density. Implications for treatment resistant schizophrenia
Andrea de Bartolomeis et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2019)
DARK Classics in Chemical Neuroscience: Atropine, Scopolamine, and Other Anticholinergic Deliriant Hallucinogens
Anton M. Lakstygal et al.
ACS CHEMICAL NEUROSCIENCE (2019)
Identification and pharmacological profile of SPP1, a potent, functionally selective and brain penetrant agonist at muscarinic M1 receptors
Lisa M. Broad et al.
BRITISH JOURNAL OF PHARMACOLOGY (2019)
Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial
Jennifer L. Phillips et al.
AMERICAN JOURNAL OF PSYCHIATRY (2019)
Altered levels of dopamine transporter in the frontal pole and dorsal striatum in schizophrenia
Hirotaka Sekiguchi et al.
NPJ SCHIZOPHRENIA (2019)
Changed gene expression in subjects with schizophrenia and low cortical muscarinic M1 receptors predicts disrupted upstream pathways interacting with that receptor
E. Scarr et al.
MOLECULAR PSYCHIATRY (2018)
Detecting a potential safety signal of antidepressants and type 2 diabetes: a pharmacovigilance-pharmacodynamic study
Spyridon Siafis et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases
Christian C. Felder et al.
NEUROPHARMACOLOGY (2018)
Allosteric modulators targeting CNS muscarinic receptors
Andreas Bock et al.
NEUROPHARMACOLOGY (2018)
Muscarinic receptor subtype distribution in the central nervous system and relevance to aging and Alzheimer's disease
E. P. Lebois et al.
NEUROPHARMACOLOGY (2018)
M1-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition
Sean P. Moran et al.
NEUROPSYCHOPHARMACOLOGY (2018)
MK-7622: A First-in-Class M1 Positive Allosteric Modulator Development Candidate
Douglas C. Beshore et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience
J. P. Kesby et al.
TRANSLATIONAL PSYCHIATRY (2018)
Current Concepts and Treatments of Schizophrenia
Piotr Stepnicki et al.
MOLECULES (2018)
Molecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine
Eric S. Wohleb et al.
CURRENT NEUROPHARMACOLOGY (2017)
Discovery of VU0467485/AZ13713945: An M4 PAM Evaluated as a Preclinical Candidate for the Treatment of Schizophrenia
Michael R. Wood et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Treating the Synapse in Major Psychiatric Disorders: The Role of Postsynaptic Density Network in Dopamine-Glutamate Interplay and Psychopharmacologic Drugs Molecular Actions
Carmine Tomasetti et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Design and Synthesis of γ- and δ-Lactarn M1 Positive Allosteric Modulators (PAMs): Convulsion and Cholinergic Toxicity of an M1-Selective PAM with Weak Agonist Activity
Jennifer E. Davoren et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Muscarinic receptor signaling contributes to atypical antipsychotic drug reversal of the phencyclidine-induced deficit in novel object recognition in rats
Masanori Miyauchi et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2017)
Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders
Daniel J. Foster et al.
NEURON (2017)
Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors-Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment
Ondrej Soukup et al.
CURRENT NEUROPHARMACOLOGY (2017)
Diverse Effects on M1 Signaling and Adverse Effect Liability within a Series of 101 Ago-PAMs
Jerri M. Rook et al.
ACS CHEMICAL NEUROSCIENCE (2017)
Challenges in the development of an M4 PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs
Michael R. Wood et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Brain--blood ratio: implications in brain drug delivery
Abhijeet D. Kulkarni et al.
EXPERT OPINION ON DRUG DELIVERY (2016)
AF710B, a Novell M1/sigma 1 Agonist With Therapeutic Efficacy on Animal Models of Alzheimer's Disease
Abraham Fisher et al.
NEURODEGENERATIVE DISEASES (2016)
Changes in BQCA Allosteric Modulation of [3H]NMS Binding to Human Cortex within Schizophrenia and by Divalent Cations
Brian Dean et al.
NEUROPSYCHOPHARMACOLOGY (2016)
Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse Model
A. Ghoshal et al.
NEUROPSYCHOPHARMACOLOGY (2016)
Prefrontal Cortex-Mediated Impairments in a Genetic Model of NMDA Receptor Hypofunction Are Reversed by the Novel M1 PAM VU6004256
Michael D. Grannan et al.
ACS CHEMICAL NEUROSCIENCE (2016)
Design and optimization of selective azaindole amide M1 positive allosteric modulators
Jennifer E. Davoren et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Further optimization of the M1 PAM VU0453595: Discovery of novel heterobicyclic core motifs with improved CNS penetration
Joseph D. Panarese et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine core
Michael R. Wood et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Discovery of the Potent and Selective M1 PAM-Agonist N-[(3R,4S)-3-Hydroxytetrahydro-2H-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side Effects
Jennifer E. Davoren et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Crystal structures of the M1 and M4 muscarinic acetylcholine receptors
David M. Thal et al.
NATURE (2016)
Evidence for Classical Cholinergic Toxicity Associated with Selective Activation of M1 Muscarinic Receptorss
Andrew Alt et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2016)
Role for the M1 Muscarinic Acetylcholine Receptor in Top-Down Cognitive Processing Using a Touchscreen Visual Discrimination Task in Mice
R. W. Gould et al.
ACS CHEMICAL NEUROSCIENCE (2015)
Discovery of dihydroquinazolinone derivatives as potent, selective, and CNS-penetrant M1 and M4 muscarinic acetylcholine receptors agonists
Yoshiharu Uruno et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Antipsychotic medication in schizophrenia: a review
John Lally et al.
BRITISH MEDICAL BULLETIN (2015)
RECENT DISCLOSURES OF CLINICAL CANDIDATES HIGHLIGHTS FROM THE SOCIETY OF MEDICINES RESEARCH SYMPOSIUM, HELD DECEMBER 4, 2014-NATIONAL HEART & LUNG INSTITUTE, LONDON, UK
S. P. Collingwood et al.
DRUGS OF THE FUTURE (2015)
Faster, better, stronger: Towards new antidepressant therapeutic strategies
Olivia F. O'Leary et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2015)
Five potential therapeutic agents as antidepressants: a brief review and future directions
Sheng-Min Wang et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2015)
Rapid antidepressant actions of scopolamine: Role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors
Andrea Navarria et al.
NEUROBIOLOGY OF DISEASE (2015)
Mitochondrial protection by the mixed muscarinic/σ1 ligand ANAVEX2-73, a tetrahydrofuran derivative, in Aβ25-35 peptide-injected mice, a nontransgenic Alzheimer's disease model
Valentine Lahmy et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2015)
Five potential therapeutic agents as antidepressants: a brief review and future directions
Sheng-Min Wang et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2015)
Cumulative Use of Strong Anticholinergics and Incident Dementia A Prospective Cohort Study
Shelly L. Gray et al.
JAMA INTERNAL MEDICINE (2015)
Editorial: Orphan GPCRs As Emerging Drug Targets
Ye Fang et al.
FRONTIERS IN PHARMACOLOGY (2015)
The M1 Muscarinic Positive Allosteric Modulator PQCA Improves Performance on Translatable Tests of Memory and Attention in Rhesus Monkeys
Henry S. Lange et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Discovery of N-sulfonyl-7-azaindoline derivatives as potent, orally available and selective M4 muscarinic acetylcholine receptor agonists
Atsushi Suwa et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
The Glutamatergic Aspects of Schizophrenia Molecular Pathophysiology: Role of the Postsynaptic Density, and Implications for Treatment
Felice Iasevoli et al.
CURRENT NEUROPHARMACOLOGY (2014)
Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer's Disease: A Systematic Review and Meta-Analysis
Chen-Chen Tan et al.
JOURNAL OF ALZHEIMERS DISEASE (2014)
Antipsychotic Drug-Like Effects of the Selective M4 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator VU0152100
Nellie E. Byun et al.
NEUROPSYCHOPHARMACOLOGY (2014)
Discovery of Naphthyl-Fused 5-Membered Lactams as a New Class of M1 Positive Allosteric Modulators
Zhi-Qiang Yang et al.
ACS MEDICINAL CHEMISTRY LETTERS (2014)
Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia
Daniel J. Foster et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2014)
Complex interplay between the P-glycoprotein multidrug efflux pump and the membrane: its role in modulating protein function
Frances Jane Sharom
FRONTIERS IN ONCOLOGY (2014)
M1 and M2 Muscarinic Receptor Subtypes Regulate Antidepressant-Like Effects of the Rapidly Acting Antidepressant Scopolamine
J. M. Witkin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Characterization of the Novel Positive Allosteric Modulator, LY2119620, at the Muscarinic M2 and M4 Receptors
Carrie H. Croy et al.
MOLECULAR PHARMACOLOGY (2014)
Scopolamine Rapidly Increases Mammalian Target of Rapamycin Complex 1 Signaling, Synaptogenesis, and Antidepressant Behavioral Responses
Bhavya Voleti et al.
BIOLOGICAL PSYCHIATRY (2013)
Antidepressant Effects of the Muscarinic Cholinergic Receptor Antagonist Scopolamine: A Review
Wayne C. Drevets et al.
BIOLOGICAL PSYCHIATRY (2013)
A Randomized Trial of a Low-Trapping Nonselective N-Methyl-D-Aspartate Channel Blocker in Major Depression
Carlos A. Zarate et al.
BIOLOGICAL PSYCHIATRY (2013)
Discovery of a selective M4 positive allosteric modulator based on the 3-amino-thieno[2,3-b]pyridine-2-carboxamide scaffold: Development of ML253, a potent and brain penetrant compound that is active in a preclinical model of schizophrenia
Uyen Le et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Agonists with supraphysiological efficacy at the muscarinic M2 ACh receptor
R. Schrage et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease
Bruce J. Melancon et al.
DRUG DISCOVERY TODAY (2013)
Assessing the prospect of donepezil in improving cognitive impairment in patients with schizophrenia
Neelam Thakurathi et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
Role of the cholinesterase inhibitors in the treatment of schizophrenia
Chi-Un Pae
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
Abundance, distribution, mobility and oligomeric state of M2 muscarinic acetylcholine receptors in live cardiac muscle
Tatiana A. Nenasheva et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2013)
Rapid regulation of depression-related behaviours by control of midbrain dopamine neurons
Dipesh Chaudhury et al.
NATURE (2013)
Blockade of Tau Hyperphosphorylation and Aβ1-42 Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic and σ1 Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimer's Disease
Valentine Lahmy et al.
NEUROPSYCHOPHARMACOLOGY (2013)
The muscarinic M1 receptor positive allosteric modulator PQCA improves cognitive measures in rat, cynomolgus macaque, and rhesus macaque
Jason M. Uslaner et al.
PSYCHOPHARMACOLOGY (2013)
Cholinergic muscarinic M4 receptor gene polymorphisms: A potential risk factor and pharmacogenomic marker for schizophrenia
Elizabeth Scarr et al.
SCHIZOPHRENIA RESEARCH (2013)
Discovery of Novel N-Substituted Oxindoles as Selective M1 and M4 Muscarinic Acetylcholine Receptors Partial Agonists
Takaaki Sumiyoshi et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
Decreased cortical muscarinic M1 receptors in schizophrenia are associated with changes in gene promoter methylation, mRNA and gene targeting microRNA
E. Scarr et al.
TRANSLATIONAL PSYCHIATRY (2013)
Dopaminergic meso-cortical projections to M1: role in motor learning and motor cortex plasticity
Jonas A. Hosp et al.
FRONTIERS IN NEUROLOGY (2013)
Cholinesterase Inhibitor Adjunctive Therapy for Cognitive Impairment and Depressive Symptoms in Older Adults with Depression
Cara L. McDermott et al.
ANNALS OF PHARMACOTHERAPY (2012)
Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic 4 (M4) receptor
James M. Salovich et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Novel M1 allosteric ligands: a patent review
Scott D. Kuduk et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2012)
Novel Allosteric Agonists of M1 Muscarinic Acetylcholine Receptors Induce Brain Region-Specific Responses That Correspond with Behavioral Effects in Animal Models
Gregory J. Digby et al.
JOURNAL OF NEUROSCIENCE (2012)
Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist
Kazuko Haga et al.
NATURE (2012)
Structure and dynamics of the M3 muscarinic acetylcholine receptor
Andrew C. Kruse et al.
NATURE (2012)
Interneuron dysfunction in psychiatric disorders
Oscar Marin
NATURE REVIEWS NEUROSCIENCE (2012)
The pharmacology of McN-A-343
Frederick J. Mitchelson
PHARMACOLOGY & THERAPEUTICS (2012)
Identification of Amides as Carboxylic Acid Surrogates for Quinolizidinone-Based M1 Positive Allosteric Modulators
Scott D. Kuduk et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
M4 muscarinic receptor knockout mice display abnormal social behavior and decreased prepulse inhibition
Hisatsugu Koshimizu et al.
MOLECULAR BRAIN (2012)
The cholinergic system and depression
Girstaute Dagyte et al.
BEHAVIOURAL BRAIN RESEARCH (2011)
The history of the cholinergic hypothesis
Antonio Contestabile
BEHAVIOURAL BRAIN RESEARCH (2011)
Impact of species variability and 'probe-dependence' on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor
S. Suratman et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative
Vanessa Villard et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2011)
Quantifying Ligand Bias at Seven-Transmembrane Receptors
Sudarshan Rajagopal et al.
MOLECULAR PHARMACOLOGY (2011)
Genetic variation in cholinergic muscarinic-2 receptor gene modulates M2 receptor binding in vivo and accounts for reduced binding in bipolar disorder
D. M. Cannon et al.
MOLECULAR PSYCHIATRY (2011)
Liquid chromatography/tandem mass spectrometry based targeted proteomics quantification of P-glycoprotein in various biological samples
Yiqun Zhang et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2011)
Heterocyclic fused pyridone carboxylic acid M1 positive allosteric modulators
Scott D. Kuduk et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Pyridine containing M1 positive allosteric modulators with reduced plasma protein binding
Scott D. Kuduk et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Cholinesterase Inhibitors as Adjunctive Therapy in Patients with Schizophrenia and Schizoaffective Disorder A Review and Meta-Analysis of the Literature
Salma R. I. Ribeiz et al.
CNS DRUGS (2010)
Genetic Susceptibility to Behavioural and Psychological Symptoms in Alzheimer Disease
B. Borroni et al.
CURRENT ALZHEIMER RESEARCH (2010)
Anticholinergic drug use and risk for dementia: target for dementia prevention
Frank Jessen et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2010)
Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders
Molly K. Larson et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2010)
A Subpopulation of Neuronal M4 Muscarinic Acetylcholine Receptors Plays a Critical Role in Modulating Dopamine-Dependent Behaviors
Jongrye Jeon et al.
JOURNAL OF NEUROSCIENCE (2010)
AC-260584, an orally bioavailable M1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model
Stefania Risso Bradley et al.
NEUROPHARMACOLOGY (2010)
Molecular Mechanisms of Action and In Vivo Validation of an M4 Muscarinic Acetylcholine Receptor Allosteric Modulator with Potential Antipsychotic Properties
Katie Leach et al.
NEUROPSYCHOPHARMACOLOGY (2010)
The validity of scopolamine as a pharmacological model for cognitive impairment: A review of animal behavioral studies
Inge Klinkenberg et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2010)
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Nanxin Li et al.
SCIENCE (2010)
Quinolizidinone Carboxylic Acids as CNS Penetrant, Selective M1 Allosteric Muscarinic Receptor Modulators
Scott D. Kuduk et al.
ACS MEDICINAL CHEMISTRY LETTERS (2010)
Neurocognitive Mechanisms in Depression: Implications for Treatment
Luke Clark et al.
Annual Review of Neuroscience (2009)
Synthesis and Structure-Activity Relationships of Allosteric Potentiators of the M4 Muscarinic Acetylcholine Receptor
J. Phillip Kennedy et al.
CHEMMEDCHEM (2009)
Pharmacological comparison of muscarinic ligands: Historical versus more recent muscarinic M1-preferring receptor agonists
Julia N. Heinrich et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2009)
Depression Case Control (DeCC) Study fails to support involvement of the muscarinic acetylcholine receptor M2 (CHRM2) gene in recurrent major depressive disorder
Sarah Cohen-Woods et al.
HUMAN MOLECULAR GENETICS (2009)
Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects
A. S. Gibbons et al.
JOURNAL OF AFFECTIVE DISORDERS (2009)
A Selective Allosteric Potentiator of the M1 Muscarinic Acetylcholine Receptor Increases Activity of Medial Prefrontal Cortical Neurons and Restores Impairments in Reversal Learning
Jana K. Shirey et al.
JOURNAL OF NEUROSCIENCE (2009)
Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia
E. Scarr et al.
MOLECULAR PSYCHIATRY (2009)
Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system
Antoine Taly et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Immediate and Delayed Consequences of Xanomeline Wash-Resistant Binding at the M3 Muscarinic Receptor
Meredith J. Noetzel et al.
NEUROCHEMICAL RESEARCH (2009)
Altered M1 Muscarinic Acetylcholine Receptor (CHRM1)-Gαq/11 Coupling in a Schizophrenia Endophenotype
Hasib Salah-Uddin et al.
NEUROPSYCHOPHARMACOLOGY (2009)
Muscarinic Receptors in Psychiatric Disorders - Can We Mimic 'Health'?
E. Scarr
NEUROSIGNALS (2009)
Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation
Lei Ma et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
The Dopamine Hypothesis of Schizophrenia: Version III - The Final Common Pathway
Oliver D. Howes et al.
SCHIZOPHRENIA BULLETIN (2009)
Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders
P. Jeffrey Conn et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia
Anantha Shekhar et al.
AMERICAN JOURNAL OF PSYCHIATRY (2008)
Antipsychotic-like behavioral effects and cognitive enhancement by a potent and selective muscarinic M-1 receptor agonist, AC-260584
Kimberly E. Vanover et al.
BEHAVIORAL NEUROSCIENCE (2008)
Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1
C. J. Langmead et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Novel Selective Allosteric Activator of the M1 Muscarinic Acetylcholine Receptor Regulates Amyloid Processing and Produces Antipsychotic-Like Activity in Rats
Carrie K. Jones et al.
JOURNAL OF NEUROSCIENCE (2008)
Centrally Active Allosteric Potentiators of the M4 Muscarinic Acetylcholine Receptor Reverse Amphetamine-Induced Hyperlocomotor Activity in Rats
Ashley E. Brady et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Therapeutic strategies for Alzheimer's disease
Donna M. Barten et al.
MOLECULAR NEUROBIOLOGY (2008)
Structural diversity of G protein-coupled receptors and significance for drug discovery
Malin C. Lagerstrom et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Cholinergic treatments with emphasis on M1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease
Abraham Fisher
NEUROTHERAPEUTICS (2008)
Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia
W. Y. Chan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Selective effects of cholinergic modulation on task performance during selective attention
Maura L. Furey et al.
NEUROPSYCHOPHARMACOLOGY (2008)
An allosteric potentiator of M-4 mAChR modulates hippocampal synaptic transmission
Jana K. Shirey et al.
NATURE CHEMICAL BIOLOGY (2008)
No evidence for association between 19 cholinergic genes and bipolar disorder
Jiajun Shi et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS (2007)
Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia
Elizabeth Scarr et al.
BIOLOGICAL PSYCHIATRY (2007)
Towards a muscarinic hypothesis of schizophrenia
T. J. Raedler et al.
MOLECULAR PSYCHIATRY (2007)
Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development
Juergen Wess et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Structural requirements of transmembrane domain 3 for activation by the M1 muscarinic receptor agonists AC-42, AC-260584, clozapine, and N-desmethylclozapine:: Evidence for three distinct modes of receptor activation
Tracy A. Spalding et al.
MOLECULAR PHARMACOLOGY (2006)
A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment
Maurizio Fava et al.
JOURNAL OF CLINICAL PSYCHIATRY (2006)
Antidepressant efficacy of the antimuscarinic drug scopolamine - A randomized, placebo-controlled clinical trial
Maura L. Furey et al.
ARCHIVES OF GENERAL PSYCHIATRY (2006)
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression
Carlos A. Zarate et al.
ARCHIVES OF GENERAL PSYCHIATRY (2006)
Investigation of M1/M4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder (vol 29, pg 619, 2004)
K Zavitsanou et al.
NEUROPSYCHOPHARMACOLOGY (2006)
M1 receptors play a central role in modulating AD-like pathology in transgenic mice
A Caccamo et al.
NEURON (2006)
Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic M-1 receptor: Direct pharmacological evidence that AC-42 is an allosteric agonist
CJ Langmead et al.
MOLECULAR PHARMACOLOGY (2006)
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice
MH Trivedi et al.
AMERICAN JOURNAL OF PSYCHIATRY (2006)
Amyloidogenic processing of beta-amyloid precursor protein in intracellular compartments
KS Vetrivel et al.
NEUROLOGY (2006)
Mammalian G proteins and their cell type specific functions
N Wettschureck et al.
PHYSIOLOGICAL REVIEWS (2005)
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
JA Lieberman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Reduced cocaine self-administration in muscarinic M5 acetylcholine receptor-deficient mice
M Thomsen et al.
JOURNAL OF NEUROSCIENCE (2005)
CHRM2 gene predisposes to alcohol dependence, drug dependence and affective disorders:: results from an extended case-control structured association study
XG Luo et al.
HUMAN MOLECULAR GENETICS (2005)
Evidence of common and specific genetic effects:: association of the muscarinic acetylcholine receptor M2 (CHRM2) gene with alcohol dependence and major depressive syndrome
JC Wang et al.
HUMAN MOLECULAR GENETICS (2004)
M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission:: relevance to the pathophysiology and treatment of related central nervous system pathologies
ET Tzavara et al.
FASEB JOURNAL (2004)
Therapeutic effect of cevimeline on dry eye in patients with Sjogren's syndrome: A randomized, double-blind clinical study
M Ono et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2004)
Thiochrome enhances acetylcholine affinity at muscarinic M-4 receptors: Receptor subtype selectivity via cooperativity rather than affinity
S Lazareno et al.
MOLECULAR PHARMACOLOGY (2004)
Association of anticholinergic load with impairment of complex attention and memory in schizophrenia
MJ Minzenberg et al.
AMERICAN JOURNAL OF PSYCHIATRY (2004)
N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity
C Sur et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The G-protein-coupled receptors in the human genome form five main families.: Phylogenetic analysis, paralogon groups, and fingerprints
R Fredriksson et al.
MOLECULAR PHARMACOLOGY (2003)
Behavioral, neurochemical, and electrophysiological characterization of a genetic mouse model of depression
M El Yacoubi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Diagnosis and definition of treatment-resistant depression
M Fava
BIOLOGICAL PSYCHIATRY (2003)
Neurocognitive impairment in drug-free patients with major depressive disorder
RJ Porter et al.
BRITISH JOURNAL OF PSYCHIATRY (2003)
Selective cognitive dysfunction in acetylcholine M-1 muscarinic receptor mutant mice
SG Anagnostaras et al.
NATURE NEUROSCIENCE (2003)
In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia
TJ Raedler et al.
AMERICAN JOURNAL OF PSYCHIATRY (2003)
Role of P-glycoprotein in pharmacokinetics - Clinical implications
JH Lin et al.
CLINICAL PHARMACOKINETICS (2003)
Deletion of the M5 muscarinic acetylcholine receptor attenuates morphine reinforcement and withdrawal but not morphine analgesia
AS Basile et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
The utility of muscarinic agonists in the treatment of Alzheimer's disease
WS Messer
JOURNAL OF MOLECULAR NEUROSCIENCE (2002)
AF150(S) and AF267B - M1 muscarinic agonists as innovative therapies for Alzheimer's disease
A Fisher et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2002)
Association of the muscarinic cholinergic 2 receptor (CHRM2) gene with major depression in women
DE Comings et al.
AMERICAN JOURNAL OF MEDICAL GENETICS (2002)
Decreased muscarinic(1) receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia
B Dean et al.
MOLECULAR PSYCHIATRY (2002)
Direct and Indirect Modulation of the N-Methyl D-Aspartate Receptor: Potential for the Development of Novel Antipsychotic Therapies
M. J. Marino et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2002)
Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice
DJ Gerber et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Hyperactivity and intact hippocampus-dependent learning in mice lacking the M1 muscarinic acetylcholine receptor
T Miyakawa et al.
JOURNAL OF NEUROSCIENCE (2001)
Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: A study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment
JM Crook et al.
AMERICAN JOURNAL OF PSYCHIATRY (2001)
Alzheimer's disease: Genes, proteins, and therapy
DJ Selkoe
PHYSIOLOGICAL REVIEWS (2001)
Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean
M Yamada et al.
NATURE (2001)
Muscarinic M1 agonists in the treatment of Alzheimer's disease
AD Korczyn
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2000)
Decreased muscarinic receptor binding in subjects with schizophrenia: A study of the human hippocampal formation
JM Crook et al.
BIOLOGICAL PSYCHIATRY (2000)
Intravenous versus oral administration of amitriptyline in patients with major depression
EA Deisenhammer et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2000)
Allosteric interactions of staurosporine and other indolocarbazoles with N-[methyl-3H] scopolamine and acetylcholine at muscarinic receptor subtypes:: Identification of a second allosteric site
S Lazareno et al.
MOLECULAR PHARMACOLOGY (2000)
Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability
IM Anderson
JOURNAL OF AFFECTIVE DISORDERS (2000)
Antidepressant effects of ketamine in depressed patients
RM Berman et al.
BIOLOGICAL PSYCHIATRY (2000)
Share Paper
